A pharma partnership that brought a breakthrough in breast cancer
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing